武漢佰樂博代理：Research Grade Labetuzumab

貨號：DHC21001

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75486.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Labetuzumab是一種人源化抗癌胚抗原(CEA)單克隆抗體，可抑制腫瘤生長并使人類髓樣甲狀腺癌異種細(xì)胞對Dacarbazine化療敏感。

通用名:Labetuzumab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內(nèi)毒素:Please contact with the lab for this information.

別名:hMN14, IMMU-130, hMN-14-SN-38, hMN-14-SN-38 ADC, hMN14-CL-SN-38, Labetuzumab Govitecan

靶點(diǎn);物種:Human CD66e/CEA/CEACAM5

種類:Humanized

受體鑒定:IgG1-kappa

CAS: 219649-07-7

存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. PMID: 28817371

Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. PMID: 10647610

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. PMID: 9441773